Mustang Bio has announced City of Hope’s report that their MB-102 (CD123 CAR) CAR T therapy is safe and has achieved the first-ever complete response from a CAR T therapy in blastic plasmacytoid dendritic cell neoplasm (BPDCN), as well as a CR in acute myeloid leukemia (AML), in an ongoing Phase 1 clinical trial.    Manuel Litchman, M.D., president and chief executive officer of Mustang, said, “According to investigators at City of Hope, these data demonstrate MB-102’s potential to be a ...